Publications by authors named "Lorie Ellis"

Claim this Profile
R
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.
Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Lorie Ellis

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.
Benjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Lorie Ellis

J Comp Eff Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.
Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Lorie Ellis

Adv Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer.
Shawn Du, Carmine Rossi, Ibrahim Khilfeh, Porpong Boonmak, Gordon Wong, Lorie Ellis

J Health Econ Outcomes Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide'[Urol Oncol: Semin Original Investigat 41(3) (2023) 253.e1-253.e9].
Benjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, Carmine Rossi, Erik Muser, Lorie Ellis

Urol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
Franklin D Gaylis, Bruno Emond, Ameur M Manceur, Anabelle Tardif-Samson, Laura Morrison, Lorie A Ellis

J Health Econ Outcomes Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.
Joseph Tkacz, Andrea Ireland, Barnabie Agatep, Lorie Ellis, Hiremagalur Balaji

J Med Econ· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Lorie A Ellis

Pharmacoecon Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Benjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, Carmine Rossi, Erik Muser, Lorie Ellis

Urol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
Benjamin Lowentritt, Dominic Pilon, Dexter Waters, Carmine Rossi, Erik Muser, Lorie Ellis

Urol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
Vincent M Bivins, Mike Durkin, Ibrahim Khilfeh, Carmine Rossi, Frederic Kinkead, Lorie Ellis

Future Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
Benjamin Lowentritt, Gordon Brown, Dominic Pilon, Lorie Ellis, Guillaume Germain

Urology· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication adherence among patients with advanced prostate cancer using oral therapies.
Dominic Pilon, Joyce LaMori, Carmine Rossi, Mike Durkin, Isabelle Ghelerter, Lorie Ellis

Future Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
David P Hudesman, Soumya D Chakravarty, Bruno Emond, Lorie A Ellis, Patrick Lefebvre

BMC Rheumatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Dominic Pilon, Lorie A Ellis, Yongling Xiao, Ajay S Behl, Patrick Lefebvre

Am J Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Bruno Emond, Lorie A Ellis, Soumya D Chakravarty, Martin Ladouceur, Patrick Lefebvre

Curr Med Res Opin· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
Stanley B Cohen, Joel M Kremer, Kimberly J Dandreo, George W Reed, Robert Magner, Lorie Ellis

Clin Rheumatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Julie Vanderpoel, Joseph Tkacz, Brenna L Brady, Lorie Ellis

Clin Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.
Lorie A Ellis, Elisabetta Malangone-Monaco, Helen Varker, Diana Stetsovsky, Maureen Kubacki

Clinicoecon Outcomes Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population.
Yusuf Yazici, Lin Xie, Adesuwa Ogbomo, Lorie A Ellis, Kavitha Goyal

Biologics· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
Yusuf Yazici, Lin Xie, Adesuwa Ogbomo, Lorie A Ellis, Kavitha Goyal

Biologics· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
Shoshana R Daniel, John D McDermott, Cathy Le, Christine A Pierce, Michael A Ziskind, Lorie A Ellis

J Med Econ· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
Raphael J Dehoratius, Lawrence H Brent, Jeffrey R Curtis, Lorie A Ellis, Kezhen L Tang

Patient· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.
Ajay S Behl, Lorie A Ellis, Dominic Pilon, Yongling Xiao, Patrick Lefebvre

Am Health Drug Benefits· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Dominic Pilon, Ajay S Behl, Lorie A Ellis, Marie-Noëlle Robitaille, Patrick Lefebvre

Am Health Drug Benefits· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis